共 13 条
- [1] Lemborexant Attenuates Regurgitation without Worsening Objective Parameters on Reflux Monitoring in Patients with Gastroesophageal Reflux Disease and Insomnia: A Single-Arm Proof-of-Concept StudyDIGESTION, 2023, 104 (06) : 438 - 445Hoshikawa, YoshimasaMomma, EriKawami, NoriyukiIwakiri, Katsuhiko
- [2] Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot studyJGH OPEN, 2024, 8 (02):Lakhtakia, SundeepSingh, Aniruddha P.Singla, NeerajMemon, Sana F.Reddy, Duvvur N.
- [3] Proton pump inhibitors as treatment of laryngeal disorders among patients with gastroesophageal reflux disease: a single-arm (pre and post) quasi-experimental studyEGYPTIAN JOURNAL OF OTOLARYNGOLOGY, 2023, 39 (01):Ragaee, Mahmoud AliSedik, Shaimaa SalahAhmed, Hanan Abd El Rasheed MohamedMahran, Essam Eldeen Mohamed OsmanRoushdy, Mohamed Mahmoud
- [4] Proton pump inhibitors as treatment of laryngeal disorders among patients with gastroesophageal reflux disease: a single-arm (pre and post) quasi-experimental studyThe Egyptian Journal of Otolaryngology, 39Mahmoud Ali RagaeeShaimaa Salah SedikHanan Abd El Rasheed Mohamed AhmedEssam Eldeen Mohamed Osman MahranMohamed Mahmoud Roushdy
- [5] A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonatesJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Hu, M. I.Gucalp, R.Insogna, K. L.Glezerman, I.Bone, H. G.Jaccard, A.Misiorowski, W.Yu, B. W.Yeh, H.
- [6] Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept studyLANCET RHEUMATOLOGY, 2022, 4 (02): : E105 - E112Matza, Mark A.Perugino, Cory A.Harvey, LiamFernandes, Ana D.Wallace, Zachary S.Liu, HangAllard-Chamard, HuguesPillai, ShivStone, John H.
- [7] Study protocol for Cognitive Behavioral Therapy for Insomnia in patients with primary brain tumor: A single-arm phase 2a proof-of-concept trialCONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 32Loughan, Ashlee R.Lanoye, AutumnWillis, Kelcie D.Fox, AmberZukas, AliciaKim, Youngdeok
- [8] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDYATHEROSCLEROSIS, 2017, 263 : E9 - E9Gaudet, DanielGipe, DanielHovingh, KeesAhmad, ZahidCuchel, MarinaShah, PredimanChyu, Kuang-YuhPordy, RobertSasiela, WilliamChan, Kuo-ChenKhoury, Etienne
- [9] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDYATHEROSCLEROSIS, 2016, 252 : E254 - E255Gaudet, D.Gipe, D. A.Khoury, E.Pordy, R.Sasiela, W.Chan, K. C.
- [10] Bravo 48-hour Wireless pH Monitoring in Patients With Non-cardiac Chest Pain. Objective Gastroesophageal Reflux Disease Parameters Predict the Responses to Proton Pump InhibitorsJOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 18 (02) : 169 - 173Karamanolis, GeorgiosTriantafyllou, KonstantinosPsatha, PanagiotaVlachogiannakos, IoannisGaglia, AsiminaPolymeros, DimitriosFessatou, SmaragdiTriantafyllou, MariaPapanikolaou, Ioannis S.Ladas, Spiros D.